Developmental Disorders is an indication for drug development with over 190 pipeline drugs currently active. According to GlobalData, preregistered drugs for Developmental Disorders have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Developmental Disorders compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Developmental Disorders overview

Developmental disorders comprise a spectrum of conditions affecting physical, cognitive, social, and behavioral aspects in children. Autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and intellectual disabilities are prominent examples. These disorders manifest early in life, impacting learning, communication, motor skills, and social interactions. Diagnosis involves developmental assessments, observations, and medical history. Treatment involves tailored interventions, including therapy, educational support, and sometimes medications to manage specific symptoms. Early identification and intervention significantly improve outcomes, aiming to enhance the child’s abilities, promote independence, and provide necessary support for both the individual and their family.

For a complete picture of PTSR and LoA scores for drugs in Developmental Disorders, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.